SANGAMO THERAPEUTICS, INC 8-K

What Happened

• Sangamo Therapeutics, Inc. (Case No. 26-10989) filed a voluntary petition for relief under Chapter 11 on June 23, 2026 and is operating as a debtor‑in‑possession. The company filed a Bidding Procedures Motion (Docket No. 13) to approve auction/bidding procedures for a potential sale of all or substantially all assets; the Bankruptcy Court entered the Bidding Procedures Order on July 14, 2026 (Docket No. 122).
• Separately, on July 14, 2026 the Nasdaq Hearings Panel issued a written determination denying Sangamo’s request to continue its listing on The Nasdaq Capital Market. The company previously received a delisting determination on April 28, 2026; trading was suspended on Nasdaq and moved to OTCQB on May 5, 2026 and currently trades on the OTCID Basic Market under the symbol SGMOQ.

Key Details

• Petition date and case: June 23, 2026; U.S. Bankruptcy Court for the District of Delaware; Case No. 26-10989.
• Bankruptcy sale timeline per Bidding Procedures Order: Bid Deadline — August 4, 2026 at 5:00 p.m. ET; Auction (if >1 qualified bid) — August 10, 2026 at 10:00 a.m. ET; Sale Hearing — August 20, 2026 at 10:00 a.m. ET.
• Nasdaq action: initial delisting determination April 28, 2026; Panel denial of continued listing July 14, 2026. Sangamo has 15 days to request review by the Nasdaq Listing and Hearing Review Council but does not intend to do so; Nasdaq is expected to file a Form 25 to delist and deregister the common stock under Section 12(b).
• Case materials and full Bidding Procedures are posted at https://www.veritaglobal.net/SangamoTherapeutics (third‑party claims/noticing agent).

Why It Matters

• Chapter 11 filing and the active sale process mean the company is seeking to maximize value for stakeholders through sale(s) or reorganization; outcomes could materially affect equity holders, creditors and employees.
• Nasdaq’s denial and likely delisting/deregistration reduce liquidity and visibility for Sangamo shares (now trading OTC), and could change investor access and regulatory reporting obligations if deregistration proceeds.
• Key near‑term dates (bids by Aug 4; auction Aug 10; sale hearing Aug 20) are important for anyone following potential buyers, asset sales, or plan sponsors.